NCT04776239View on ClinicalTrials.gov

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

March 30, 2025

Study Completion Date

August 26, 2025

Conditions
Diabetes MellitusIschemic Heart Disease
Interventions
DRUG

100 million Allogeneic Mesenchymal Human Stem Cells

1 single intravenous infusion

OTHER

Placebo

Placebo delivered via peripheral intravenous infusion

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Joshua M Hare

OTHER

NCT04776239 - Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) | Biotech Hunter | Biotech Hunter